Nektar Wins $90 Million Verdict Against Eli Lilly Over Rezpeg Partnership
California jury found Lilly breached good faith in the 2017 rezpeg deal and awarded Nektar $90 million plus interest. Lilly plans to appeal.
/ 7 items
#NKTR↓
Nektar Shares Slide as Jury Weighs Lilly Lawsuit Over Rezpeg
Investors are watching liability and damages in Nektar’s breach case against Lilly, a key swing factor for the Rezpeg program. Analysts still see damages as the hard issue.
AbbVie Bolsters Immunology Pipeline with $10.9 Billion Apogee Acquisition
The acquisition would add a longer-acting alternative to Dupixent for inflammatory diseases.
New Drug Shows Stronger Hair Regrowth After 1 Year in Severe Alopecia Areata
Nektar drug showed promising hair regrowth in severe alopecia areata after 52 weeks, with good safety and twice-monthly shots.
William Blair Upgrades Nektar on Strong Rezpeg Drug Data
William Blair upgrades Nektar to Outperform following promising long-term data for rezpegaldesleukin in atopic dermatitis treatment with improved safety profile. The results met and in some cases exceeded investor expectations.
Nektar's Alopecia Drug Shows Promise But Raises Concerns
Nektar's (NKTR) rezpegaldesleukin demonstrates hair regrowth in alopecia areata patients but narrowly misses primary endpoint, presenting mixed results as company advances to Phase 3 trials.